Firma Bayer, Autor bei PR-Web

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)

Posted on 17. November 2023 by Firma Bayer Posted in Research / Development Tagged aav, aav2, askbio, askbios, asklepios, bayer, brain, exploration, gdnf, girdle, market, patients, quest, statements, with

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in the brain for the treatment of MSA-P / Phase 1 randomized, controlled trial to assess safety of AB-1005 delivered to the putamen in patients […]

AskBio Contribution to Advancing Gene Therapy Highlighted at ESGCT 30th Congress

Posted on 23. October 202324. October 2023 by Firma Bayer Posted in Research / Development Tagged askbio, askbios, bayer, brain, dbdna, girdle, market, mice, p340, statements, taav, thurs, touchlight, viralgen, with

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that 20 company abstracts will be presented at the European Society for Gene and Cell Therapy (ESGCT) 30th Congress, which is being held in Brussels, […]

AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

Posted on 3. August 20233. August 2023 by Firma Bayer Posted in Research / Development Tagged aav, askbio, askbios, bayer, columbus, fkrp, girdle, lgmd, lgmd2i, market, moran, neurotherapeutics, patients, statements, with

Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been dosed in the Phase 1 / Phase 2 LION-CS101 clinical trial of patients […]

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies

Posted on 3. August 20233. August 2023 by Firma Bayer Posted in Research / Development Tagged bayer, bemdaneprocel, bluerock, brt, crispr, da01, forecast, ipsc, liver, patients, royalties, statements, tregs, versant, with

Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. / Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as […]

BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson’s disease clinical trial

Posted on 14. March 202314. March 2023 by Firma Bayer Posted in Research / Development Tagged bayer, bluerock, brain, brt, cancer, cell, da01, gold, parkinsons, patients, statements, uhn, versant, wireless, with

Rune Labs’ StriveStudy platform and Emerald Innovations’ Emerald wireless monitoring sensor will passively capture data on Parkinson’s disease impact on function of fifty study participants in BlueRock’s global non-interventional clinical study. / Collaboration is part of BlueRock’s commitment to change […]

BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson’s Disease

Posted on 31. May 2022 by Firma Bayer Posted in Research / Development Tagged bayer, bluerock, brain, brt, cancer, cell, cells, da01, patients, securities, statements, transplant, uhn, versant, with

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). The purpose of the Ph1 […]

AskBio and Touchlight Restructure Joint Venture

Posted on 8. February 20228. February 2022 by Firma Bayer Posted in Research / Development Tagged aav, askbio, askbios, asklepios, bayer, cell, clinical, hemophilia, market, plasmid, production, statements, touchlight, vaccines, with

– Restructuring Provides Parallel Rights to Manufacture and Sell doggybone DNA (dbDNA™) into the AAV market as Independent CDMO Businesses – AskBio Secures 100% Ownership of TAAV Manufacturing Solutions, SL to Manufacture AAV doggybone DNA (dbDNA) Technology from San Sebastian, […]

Bayer Consumer Health names Dr. Ricardo Salazar Hernández Chief Medical Officer

Posted on 2. February 2022 by Firma Bayer Posted in General Tagged bayer, cdm, chc, company, financial, healthcare, hernndez, masters, medical, new, risks, salazar, statements, sur, with

Today Bayer announced Dr. Ricardo Salazar Hernández as the new Chief Medical Officer of the Consumer Health division starting May 1st. In his new role, Dr. Salazar will lead the Global Medical Affairs function with responsibilities over medical insights, claims […]

BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson’s Disease

Posted on 6. January 20226. January 2022 by Firma Bayer Posted in Research / Development Tagged bayer, bluerock, brain, cell, cells, clinical, patients, ph1, power, securities, statements, therapy, transplant, versant, with

BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced […]

Vividion Therapeutics Announces Formation of Scientific Advisory Board

Posted on 22. September 202122. September 2021 by Firma Bayer Posted in Research / Development Tagged bayer, breast, cancer, diabetes, evergrande, idh1, idh2, mikala, mtor, patients, psoriasis, sequencing, solit, vividion, with

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the […]